Previous Close | 1.7500 |
Open | 1.8860 |
Bid | 1.7200 x 0 |
Ask | 1.7340 x 0 |
Day's Range | 1.7020 - 1.8860 |
52 Week Range | 1.5600 - 7.2000 |
Volume | |
Avg. Volume | 117,244 |
Market Cap | 379.406M |
Beta (5Y Monthly) | 1.01 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.7100 |
Earnings Date | Apr 25, 2022 - Apr 29, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 4.75 |
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of the patient enrollment for the 600 mg dose cohort from Alligator's Phase I, first-in-human clinical trial with the 4-1BB (CD137) targeting drug candidate, ATOR-1017, which is being developed as a tumor-directed therapy for
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the ongoing OPTIMIZE-1 clinical Phase Ib/II trial in first-line metastatic pancreatic cancer with the company's lead asset, mitazalimab. Safety evaluation of the second dose-escalation cohort (900 µg/kg of mitazalimab in combination with mFOLFIRINOX) has concluded, which marks the successful completion of the Phase Ib part of the study. The Data Review Committee has declared the 900 µg/kg mitazalimab dose to be safe and
OPTIMIZE-1 Phase II - On Track and Moving Forward